Ainos, Inc. (AIMD)

US — Healthcare Sector
Peers: TNON  SSKN  NPCE  MOVE  OSA  KIDS  ANIK  HSKA  CVRX  OFIX  AORT 

Automate Your Wheel Strategy on AIMD

With Tiblio's Option Bot, you can configure your own wheel strategy including AIMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AIMD
  • Rev/Share 0.0067
  • Book/Share 0.8272
  • PB 0.7632
  • Debt/Equity 0.9145
  • CurrentRatio 2.0027
  • ROIC -0.5376

 

  • MktCap 13232174.0
  • FreeCF/Share -0.3523
  • PFCF -2.3677
  • PE -0.6751
  • Debt/Assets 0.4554
  • DivYield 0
  • ROE -0.8807

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Water Tower Research Highlights Ainos' AI Nose Accuracy Breakthrough in Elderly Care Monitoring: SmellTech Gets Smarter
AIMD
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral

AI Nose accuracy in elderly care improved to 85% with additional Smell ID training AI-friendly healthcare policies to provide tailwinds for commercial rollout SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 3, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting a significant milestone in the Company's AI Nose project for elderly care. AI Nose has reached approximately 85% accuracy in excretion odor detection-improving over the recently met internal milestone of 80%.

Read More
image for news Water Tower Research Highlights Ainos' AI Nose Accuracy Breakthrough in Elderly Care Monitoring: SmellTech Gets Smarter
Ainos Showcases Breakthrough AI Nose Technology at COMPUTEX 2025 with Japan's Robotics Partner
AIMD
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

Robotic Smell Intelligence Goes Live at Asia's Premier AI Tech Stage SAN DIEGO, CA / ACCESS Newswire / May 22, 2025 / Ainos, Inc. (NASDAQ:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer in AI-driven scent digitization, announced the official debut of its proprietary AI Nose platform at COMPUTEX 2025, alongside ugo, Inc, Japan's top service robotics company. This milestone marks the first public demonstration of real-time robotic olfaction-a new sensory category poised to transform smart robotics, environmental AI, and safety infrastructure.

Read More
image for news Ainos Showcases Breakthrough AI Nose Technology at COMPUTEX 2025 with Japan's Robotics Partner
Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy
AIMD
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral

Early results show steroid-free remission, opening pathway into $13B global pet dental health market VELDONA delivers consistent anti-inflammatory effects, strengthening Ainos' positioning in companion animal immunotherapy SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 19, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer of low-dose oral interferon therapeutics, today announced compelling interim results from its ongoing veterinary clinical trial using low-dose interferon VELDONA for treating Feline Chronic Gingivostomatitis ("FCGS"), a chronic inflammatory conditions in cats. The interim results demonstrate meaningful improvements in inflammation and a consistent reduction in steroid dependency, indicating strong commercial and scientific potential for a novel class …

Read More
image for news Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy
Ainos Reports First Quarter 2025 Financial Results
AIMD
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral

Q1 revenues increased 412% year over year, driven by AI Nose products Delivers strong turnaround from gross loss to gross profit in Q1 AI Nose gains traction beyond healthcare with strategic partnerships in robotics and semiconductor sectors VELDONA® program advances with TFDA and IRB Approvals for two clinical trials in Taiwan SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 12, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Q1 2025 represents …

Read More
image for news Ainos Reports First Quarter 2025 Financial Results
Ainos and ugo Complete First Robotic Smell Integration in Japan
AIMD
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral

Milestone Ignites a New Era of Smell-Enabled Robotics Installs AI Nose in ugo Robot; Real-World Pilots to Begin in Weeks SAN DIEGO, CA / ACCESS Newswire / April 21, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, has successfully installed its proprietary AI Nose olfaction module on a humanoid robot developed by ugo, Inc. ("ugo"), Japan's top service robotics company. Completed on April 9, 2025, the installation marks the world's first robot with a functional sense of smell, a breakthrough that redefines the frontier of robotics, AI, and human-machine interaction.

Read More
image for news Ainos and ugo Complete First Robotic Smell Integration in Japan
Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here
AIMD
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral

Practical partnership for AI Nose, multiple new opportunities AI Nose to change robotics landscape with first AI smell sensing SAN DIEGO, CA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of smell digitization, today announced that Water Tower Research ("WTR") has published a report on the Company's strategic partnership with ugo, Inc., a leading Japanese service robotics company. The collaboration will integrate Ainos' innovative AI Nose technology into ugo's service robots, marking a milestone in digitizing olfactory sensing.

Read More
image for news Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here
Ainos and ugo to Develop the World's First Robot With a Sense of Smell
AIMD
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral

A Major Breakthrough in Ainos' Mission to Digitize Scent First-ever Smell-Enabled Robotics Will Unlock New Revenue Streams in Smart Manufacturing, Public Safety and more SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW), a pioneer of smell digitization, and ugo, Inc., Japan's largest service robot company by market share1, today announced a strategic partnership to integrate Ainos' AI Nose technology with ugo's autonomous robotic platform. This collaboration will mark a major milestone in the digitization of smell, unlocking new capabilities for robots in industrial safety, healthcare, and public security.

Read More
image for news Ainos and ugo to Develop the World's First Robot With a Sense of Smell

About Ainos, Inc. (AIMD)

  • IPO Date 2021-01-08
  • Website https://ainos.com
  • Industry Biotechnology
  • CEO Mr. Chun-Hsien Tsai
  • Employees 44

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.